Debt ManagementThe company renegotiated its debt with Novaquest, converting a large portion of it into equity, and pushing out cash payments to June 2027.
Market ExpansionHansa secured reimbursement for Idefirix in both Australia and Switzerland.
Treatment PotentialImlifidase has the potential to be the standard of care for Guillain-Barre Syndrome due to its rapid action in reducing total IgG levels, fitting the ideal treatment window for the disease.